Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Eliglustat for Gaucher’s disease: trippingly on the tongue

Gaucher’s disease is a rare inherited disorder resulting from a deficiency of β glucosidase and accumulation of substrate glucosyl ceramide; patients in the UK are identified once they have become symptomatic, although often a delay occurs from onset of clinical manifestations to diagnosis.1 Intravenous enzyme replacement therapy (ERT) is the mainstay of Gaucher’s disease treatment, introduced in the 1990s. Three distinct recombinant preparations are currently available—two preparations approved in Europe and three by the Food and Drug Administration in the USA.